Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan for prevention of anthracycline-related cardiotoxicity in high-risk cancer patients
RBR-5q4gm5bPhase 3Recruiting
- Sponsor
- Hospital Erasto Gaertner
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan in Anthracycline Cardiomyopathy and heart failure (HF) (2 arms), sponsored by Hospital Erasto Gaertner. Started Feb 2022; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
Anthracycline Cardiomyopathyheart failure (HF)
Beyond the preview
Go deeper on RBR-5q4gm5b.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-5q4gm5b.